6 results
425
CELG
Celgene Corporation
19 Mar 19
Business combination disclosure
7:04am
its20 Phase 1 and 2 clinical programs, presented a greater value creation opportunity than other strategic alternatives given:the scarcity … Acquisition Resulted From a Robust Strategic Review Given the scarcity of attractive biotech opportunities, high premiums paid in bolt-on acquisitions
425
CELG
Celgene Corporation
6 Mar 19
Business combination disclosure
7:03am
’ opportunities as an alternative The Celgene Acquisition Resulted From a Robust Strategic Review Given the scarcity of attractive biotech opportunities
425
5gp5ou7m7r2ezf0zdo
6 Mar 19
Business combination disclosure
7:00am
- Prev
- 1
- Next